Skip to main content
. Author manuscript; available in PMC: 2022 Sep 1.
Published in final edited form as: Antiviral Res. 2021 May 30;193:105084. doi: 10.1016/j.antiviral.2021.105084

Fig. 5.

Fig. 5.

Structures of the selected compounds used in the screening assays against rCedV-Luc infection in HEK 293T and Vero E6 cell lines. A1: 3-(1-(6-(cyclopropylamino)pyrimidin-4-yl)piperidin-4-yl)-N-(pyridin-3-ylmethyl)propenamide; A2: 3-(1-(6-(cyclopropylamino)pyrimidin-4-yl)piperidin-4-yl)-N-(2,4-difluorobenzyl)propenamide; A3: (1-(6-(cyclopropylamino)pyrimidin-4-yl)piperidin-4-yl)-N-(2-(thiophen-2-yl)ethyl)propenamide; B1: N-(3,4-dimethoxyphenyl)-3-(3-(4-(pyrrolidin-1-yl)phenyl)-1,2,4-oxadiazol-5-yl)propenamide; B2: N-(3-morpholinopropyl)-3-(3-(4-(pyrrolidin-1-yl)phenyl)-1,2,4-oxadiazol-5-yl)propenamide; C1: cyclobutyl(1-(4-ethoxyphenyl)-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)methanone; F1: cyclobutyl(1-(4-ethoxyphenyl)-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)methanone; Z: 3-(1-(4-bromo-2-fluorophenyl)-5-methyl-1H-1,2,3-triazol-4-yl)-N-(4-methoxyphenyl)-1,2,4-thiadiazol-5-amine.